Leap Therapeutics, Inc.'s DKN-01 showed disappointing results in the DisTinGuish trial for gastric and gastroesophageal junction cancer. The DeFianCe trial in colorectal cancer was closer to ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric cancer. Read more here.

What is stenosis after gastric bypass surgery? After gastric bypass surgery for weight loss, the new connection between the stomach pouch and the small intestine may narrow. This is called an ...

ALX Oncology will host a webcast on January 23 to discuss updated ASPEN-06 trial data for evorpacept in gastric cancer. ALX Oncology Holdings Inc. will host a virtual event on January 23 at 1:00 p ...